Keywords: vanguard, licenses, endothelin, antagonist, medica, signed, agreement

Vanguard Licenses Endothelin Antagonist

Article | 10 September 1998

Print This

Vanguard Medica has signed an agreement with Roche for the developmentof a selective endothelin A antagonist, Ro 61-1790, as a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in